文献速递血液净化与透析

血液透析滤过相比高通量血液透析可减轻终末期肾病患者的中性粒细胞胞外诱捕网形成

Hemodiafiltration Attenuates NETosis Compared With High-Flux Hemodialysis in End-Stage Kidney Disease Patients.
PubMed 文献 · Kidney Int Rep · 2025-06-10

本研究纳入20例维持性血液透析患者(10例合并糖尿病,10例不合并糖尿病),先接受血液透析滤过(HDF)治疗并于治疗前后采血,随后转换为高通量血液透析(HFHD)治疗,在转换后1周和3周再次采血。结果显示,与HDF相比,HFHD治疗后NETosis活化和标志物显著增加,且合并糖尿病患者的NETosis标志物显著低于不合并糖尿病患者。

要点

  • 与HDF相比,HFHD治疗后NETosis活化和标志物显著增加。
  • HFHD治疗3周后血清NETosis标志物显著升高。
  • 合并糖尿病患者的NETosis标志物显著低于不合并糖尿病患者。

核心结论

  • 与HDF相比,HFHD治疗3周后NETosis标志物增加,突显HDF在减轻失调的NETosis中的作用。
  • 需要进一步研究以探索不同患者群体间NETosis谱的差异,并基于透析模式评估其临床意义。

研究设计与样本

  • 研究纳入20例接受HDF治疗的血液透析患者,其中10例合并糖尿病、10例不合并糖尿病。
  • 在HDF治疗前后采集血样,转换为HFHD治疗后第1周和第3周再次采血。
  • 分离中性粒细胞,经佛波醇-12-肉豆蔻酸酯-13-乙酸酯刺激后,采用流式细胞术检测PAD4、NE、MPO、组蛋白H3和dsDNA等NETosis标志物。
  • 采用酶联免疫吸附试验检测血清citH3、MPO和NE水平。

主要发现

  • 与HDF治疗相比,HFHD治疗后NETosis活化和标志物显著增加。
  • HFHD治疗3周后血清NETosis标志物显著升高。
  • 合并糖尿病患者的NETosis标志物显著低于不合并糖尿病患者。

局限性

  • 需要进一步研究以探索不同患者群体间NETosis谱的差异,并基于透析模式评估其临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with chronic kidney disease (CKD) and diabetes mellitus face a heightened risk of cardiovascular complications and infections, potentially exacerbated by dysregulated NETosis. Given the superior survival rates observed with hemodiafiltration (HDF) over high-flux hemodialysis (HD; HFHD) and the documented NETosis dysregulation in HD and in patients with diabetes mellitus, this study aimed to investigate the impact of dialysis modality on NETosis activity in patients on HD, stratified by diabetes status. METHODS: A total of 20 patients on HD (10 with diabetes, 10 without diabetes) undergoing HDF treatment were recruited. Blood samples were collected before and after HDF. After transition to HFHD treatment, blood samples were taken again after 1 and 3 weeks of HDFD treatment. Neutrophils were isolated, stimulated with phorbol-12-myristate-13-acetate, and stained for the following NETosis markers: peptidyl arginine deiminase 4 (PAD4), neutrophil elastase (NE), myeloperoxidase (MPO), histone H3, and double-stranded DNA (dsDNA). Data were acquired using a flow cytometer. In addition, serum levels of citrullinated histone H3 (citH3), MPO, and NE were measured using enzyme-linked immunosorbent assay. RESULTS: Our results demonstrate a significant increase in NETosis activation and markers after HFHD treatment compared with HDF treatment. NETosis markers significantly increased in serum after 3 weeks of HFHD treatment. In addition, significantly lower NETosis markers were observed in patients with diabetes than in patients without diabetes. CONCLUSION: The increase in NETosis markers after 3 weeks of HFHD compared with HDF highlights the role of HDF in mitigating dysregulated NETosis. Further research is needed to explore differences in NETosis profiles across patient populations and assess their clinical implications based on dialysis modality.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Remez-Gabay L, Vdovich O, Andrawes Barbara FY, et al. Hemodiafiltration Attenuates NETosis Compared With High-Flux Hemodialysis in End-Stage Kidney Disease Patients. Kidney Int Rep. 2025. PMID: 40980683. doi:10.1016/j.ekir.2025.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。